首页 | 本学科首页   官方微博 | 高级检索  
     


PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
Authors:T. Lissitchkov  L. Rusen  P. Georgiev  J. Windyga  R. Klamroth  L. Gercheva  L. Nemes  A. Tiede  J. Bichler  S. Knaub  L. Belyanskaya  O. Walter  K. J. Pasi
Affiliation:1. Department of Clinical Haematology in Haemorrhagic Diathesis and Anaemia, Specialized Hospital for Active Treatment “Joan Pavel”, Sofia, Bulgaria;2. Sanador SRL, Bucharest, Romania;3. Clinic of Haematology, University Multiprofile Hospital for Active Treatment “Sveti Georgi” and Medical University, Plovdiv, Bulgaria;4. Department of Disorders of Haemostasis and Internal Medicine, Institute of Haematology and Transfusion Medicine, Warsaw, Poland;5. Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany;6. Clinic of Clinical Haematology, Multiple Hospital for Active Treatment “Sveta Marina”, Varna, Bulgaria;7. Medical Centre, Hungarian Defence Forces, National Haemophilia Centre, Budapest, Hungary;8. Clinic for Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;9. Octapharma AG, Lachen, Switzerland;10. The Royal London Hospital, Barts and the London School of Medicine and Dentistry, London, UK;11. Correspondence: K. John Pasi, The Royal London Hospital, Whitechapel Road, Whitechapel, London E1 1BB, UK.;12. Tel.: +44 20 3594 1869;13. fax: +44 20 3594 1857;14. e‐mail:
Abstract:
Keywords:haemophilia A  human‐cl rhFVIII  Nuwiq®    personalized prophylaxis  pharmacokinetics  recombinant FVIII
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号